SC US (TTGP), LTD.SC US (TTGP), LTD.

Institutional investor · Portfolio as of Q4 2019

Top Holdings9 positions

Checking export access…
Activity:
MDLAMDLADelisted

MEDALLIA INC

44.4M$1.4B59.3%——
2 qtrssince 2019-Q3
Unchanged
0

HEALTH CATALYST INC

6.2M$214.4M9.2%$30.31+12.57%
2 qtrssince 2019-Q3
Unchanged
0
PDDPDD
ADR

PINDUODUO INC-ADR

5.3M$199.1M8.5%$24.80+52.50%
4 qtrssince 2019-Q1
Unchanged
0

GUARDANT HEALTH INC

2.3M$181.8M7.8%$76.70+118.34%
4 qtrssince 2019-Q1
Decreased
0

SNAP INC - A

7.4M$121.2M5.2%$11.02-43.47%
4 qtrssince 2019-Q1
Unchanged
0

BRIDGEBIO PHARMA INC

2.5M$89.2M3.8%$26.97+29.96%
3 qtrssince 2019-Q2
Unchanged
0

SQUARE INC - A

1.3M$83.6M3.6%$74.92-17.51%
4 qtrssince 2019-Q1
Decreased
0

QUINCE THERAPEUTICS INC

1M$58.4M2.5%$42.51+32.04%
3 qtrssince 2019-Q2
Unchanged
0
EBEBDelisted

EVENTBRITE INC

42,102$849,0000.0%$17.49+15.84%
2 qtrssince 2019-Q3
Decreased
0
$2.3B
AUM
9
Positions
Q4 2019
Filing
HI score · 2.5/5
Quarterly 13F Value Change
+42%Q2'19$1.5B+54%Q3'19$2.3B+3%Q4'19$2.3B
Activity profile
$ moved · Q4'19
New0%Increased0%Decreased9%Exited91%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.1 quarters
<1Q0%1-4Q100%1-2Y0%2Y+0%

SC US (TTGP), LTD. manages $2.3B across 9 positions as of Q4 2019. Top holdings: MDLA (59.3%), HCAT (9.2%), PDD (8.5%). Fund DNA: Concentrated Value. HoldingsIntel Score: 2.5/5.0.

Q4 2019 Summary

Exited 1, trimmed 3. No standout high-conviction moves this quarter. Portfolio: $2.3B across 9 positions.

Top holdings by portfolio weight

Total AUM$2B
MDLA59.29%
HCAT9.20%
PDD8.54%
GH7.80%
SNAP5.20%
BBIO3.83%
XYZ3.59%
QNCX2.51%
EB0.04%
UBER0.00%

Portfolio allocation by GICS sector

Sectors5
Unknown59.29%
Healthcare23.34%
Consumer Cyclical8.54%
Communication Services5.24%
Technology3.59%

Behavioral investing profile

Checking access…
Concentrated Value- primarily Unknown, Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Solid(2.5 / 5.0)
Holdings P&L47
Conviction38
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
2Q
FIGFIGFIGMA INC
Q1 2026 → Q2 2026+1.5M shares-$460.5M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used